Clinical trials: Mental Disorder
Erectile Dysfunction
A Phase 1 Trial of LIB-01 in Healthy Participants.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetics of LIB-01 in healthy male participants.
- Trial name
- NCT06324006
- Testing
- LIB-01
- Where
- Sweden
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Dicot AB
Schizophrenia
A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia
The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia.
- Trial name
- NCT01212575
- Where
- 13 sites in Denmark
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Cognitive Impairments, Alzheimer Disease
Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment
The aim of the study is to evaluate the beneficial effect of a mixture of vegetal oils with a composition related to short, medium and long unsaturated chain fatty acids on patients with a diagnose of cognitive impairment or mild…
- Trial name
- NCT02778581
- Testing
- Lipidic Blend 1, Lipidic Blend 2
- Where
- 2 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Team Foods Colombia S.A.
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER fixed doses versus placebo in the treatment of outpatients with major depressive disorder.
- Trial name
- NCT00969709
- Testing
- Levomilnacipran ER
- Where
- 38 sites in United States
- Volunteers
- 724 people
- Sponsor
- Forest Laboratories
Premenstrual Dysphoric Disorder ( PMDD)
YAZ Premenstrual Dysphoric Disorder (PMDD) in China
The purpose of this study is to evaluate the efficacy and safety of YAZ compared to placebo in the treatment of symptoms related to Premenstrual Dysphoric Disorder (PMDD).
- Trial name
- NCT00824187
- Testing
- EE20/DRSP(YAZ, BAY86-5300)
- Where
- 16 sites in China
- Volunteers
- 187 people
- Sponsor
- Bayer
Premature Ejaculation
Exploratory Study of Pagoclone in Men With Premature Ejaculation.
The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation.
- Trial name
- NCT00370981
- Testing
- pagoclone
- Where
- 16 sites in United States
- Volunteers
- 100 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Schizophrenia
A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia
A 1-year outpatient study to test the safety and tolerability of a new medication in the treatment of schizophrenia
- Trial name
- NCT00088621
- Testing
- Lurasidone 80mg tablet
- Where
- 21 sites in United States
- Volunteers
- 61 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention Deficit Hyperactivity Disorder
An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder
A single arm, open-label, phase 3 multicenter study to evaluate the effectiveness and tolerability of atomoxetine (given once daily, target dose 1.2 mg/kg/day), as perceived by patients, parents and physicians, and its impact on…
- Trial name
- NCT00191516
- Testing
- Atomoxetine
- Where
- Germany
- Volunteers
- 257 people
- Sponsor
- Eli Lilly and Company
Mild Cognitive Impairment, MCI
Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment
Cognitive therapy software for improving cognitive function for patients with mild cognitive impairment
- Trial name
- SB-DEX (NCT06264557)
- Testing
- SB-100, Educational book
- Where
- 12 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Rowan
Anxiety, Fear
An Exploratory Investigation of a CBD Supplement's Impact on Sleep, Stress, and Focus
A high-quality broad-spectrum cannabidiol supplement with a bio-terpene complex will be administered once daily. It is hypothesized that this supplement will lead to improvements in sleep, focus, and stress.
- Conditions
- Anxiety, Fear, Stress, Low Mood
- Trial name
- NCT05518019
- Testing
- The Daily Supplement
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Prima CBD
Autism Spectrum Disorder
Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.
This is a 20-week open-label study to evaluate the safety and efficacy of full-spectrum medicinal cannabis plant extract < 0.08% THC (FEN164) in children with Autism Spectrum Disorder.
- Trial name
- NCT05516407
- Testing
- FEN164
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Fenix Innovation Group
Insomnia
Appraising Clinical Trial Experiences of Patients With Insomnia
Medical research participation percentages haven't always been fully representative of a given demographic. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it…
- Trial name
- NCT05978271
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Dementia, Frontotemporal
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VES001 in Healthy Participants
This is a Phase 1, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of VES001 in a two part followed by a…
- Trial name
- SORT-IN-1 (NCT06226064)
- Testing
- VES001
- Where
- Netherlands
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Vesper Biotechnologies ApS
Restless Legs Syndrome
Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)
The purpose of the study is to show that Rotigotine improves Restless Legs Syndrome (RLS) symptoms in subjects with moderate to severe RLS during both day and evening.
- Trial name
- RESTORE (NCT01569464)
- Testing
- Rotigotine
- Where
- 18 sites in United States
- Volunteers
- 150 people
- Sponsor
- UCB Pharma
Anxiety Generalized
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects…
- Trial name
- NCT05407064
- Testing
- MM120
- Where
- 22 sites in United States
- Volunteers
- 198 people
- Sponsor
- Definium Therapeutics US, Inc.
Substance Dependence
Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809
GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders.
- Trial name
- NCT00437632
- Testing
- GSK598809, Caffeine
- Where
- United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.
- Trial name
- NCT00490516
- Testing
- ACP-104
- Where
- 21 sites in United States
- Volunteers
- 247 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Impotence
Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection
To determine if men prefer tadalafil or sildenafil for getting and keeping an erection after treatment with both drugs.
- Trial name
- NCT00547092
- Testing
- tadalafil, sildenafil
- Where
- United Kingdom
- Volunteers
- 386 people
- Sponsor
- Eli Lilly and Company
Sleep Initiation and Maintenance Disorders, Insomnia
Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with…
- Trial name
- NCT00354809
- Testing
- GW679769
- Where
- 24 sites in United States, France and 1 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Schizophrenia
A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics
The primary purpose of the study is to compare the rate of hospitalization associated with psychotic relapse in participants with schizophrenia treated one year before with oral antipsychotics and one year after with long acting…
- Trial name
- REALAI (NCT02712463)
- Where
- 11 sites in Brazil, Mexico
- Volunteers
- 310 people
- Sponsor
- Janssen-Cilag Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.